Group 1 - The company reported a revenue of RMB 101 million for the six months ending June 30, 2025, highlighting its growth in the genetic testing sector [1] - The PGT-A test kit received China's first "National Innovative Medical Device Special Approval" Class III medical device registration certificate, indicating a significant regulatory achievement [1] - The company launched the BKA-210 intelligent sperm quality analyzer, which can complete non-invasive and accurate sperm quality analysis in three minutes, enhancing testing efficiency through AI algorithms [1] Group 2 - The acquisition of Singapore's BMX allowed the company to obtain the internationally leading Geri® time-lapse embryo incubator and Gems® embryo culture medium, marking a successful transition from imported to domestic products [2] - The Geri® incubator received a Class II medical device registration certificate from Jiangsu Drug Administration in July 2025, which is expected to significantly improve embryo quality and pregnancy success rates [2] - The company has established a sales and service network covering multiple countries and regions, with products certified by FDA, CE, and TGA, enhancing its global brand influence and facilitating the promotion of domestic products [2]